12:00 AM
 | 
Dec 24, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Scenesse afamelanotide: Phase IIa data

Top-line data from the open-label, U.S. Phase IIa CUV102 trial in 41 evaluable patients with generalized vitiligo showed that 4 doses of monthly 16 mg subcutaneous Scenesse plus thrice-weekly narrow-band ultraviolet B (NB-UVB) light met the co-primary endpoints of improving VASI and VETF scores from baseline to 6 months vs. NB-UVB alone (p=0.025 and p=0.023, respectively). Scenesse plus NB-UVB non-significantly improved median time to first repigmentation, a secondary endpoint, vs....

Read the full 329 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >